Odonate Therapeutics Inc (OQ:ODT)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 4747 Executive Dr Ste 510
SAN DIEGO CA 92121-3100
Tel: N/A
Website: https://www.odonate.com
IR: See website
Key People
Kevin C. Tang
Chairman of the Board, Chief Executive Officer
Jeff L. Vacirca
Vice Chairman of the Board
Michael S. Hearne
Chief Financial Officer
John G. Lemkey
Chief Operating Officer
Joseph P. O'Connell
Chief Medical Officer
Business Overview
Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).
Financial Overview
For the fiscal year ended 31 December 2018, Odonate Therapeutics Inc revenues was not reported. Net loss increased from $32.7M to $89M. Higher net loss reflects Research and development increase from $25.3M to $74.3M (expense), Stock-based Compensation in SGA increase from $551K to $9.8M (expense), Stock-based Compensation in R&D increase from $2.6M to $5.7M (expense).
Employees: 117 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $449.51M as of Dec 31, 2018
Annual revenue (TTM): $0.00M as of Dec 31, 2018
EBITDA (TTM): -$90.41M as of Dec 31, 2018
Net annual income (TTM): -$88.96M as of Dec 31, 2018
Free cash flow (TTM): -$69.00M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 26,752,669 as of Feb 4, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization